A federal jury in Illinois last week ordered drug manufacturer Lilly to pay more than $61 million in damages for misstating its average manufacturer prices (AMP) and underpaying Medicaid drug rebates.
AMP is a key component used to determine 340B prices and the rebates that drug manufacturers must provide to state Medicaid programs under the Medicaid rebate program. Over the past two decades, dozens of drug manufacturers have been required by the U.S. Department of Justice to refund Medicaid programs, and in some instances 340B providers, for overcharges.
A federal jury in Illinois last week ordered drug manufacturer Lilly to pay more than $61 million in damages for misstating its average manufacturer prices (AMP) and underpaying Medicaid drug rebates.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
